We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Success in translational research: lessons from the development of bortezomib.
- Authors
Sánchez-Serrano, Ibis; Sánchez-Serrano, Ibis
- Abstract
The high price of many innovative drugs, which is in part due to the considerable expense and risk involved in drug development, underlines the need for more efficient approaches to bring drugs to the market, with more effective translational research in particular identified as an important part of such strategies. Here, the development of the cancer drug bortezomib (Velcade; Millennium Pharmaceuticals) by a biotechnology company - Myogenics/ProScript - started by academics from Harvard University is discussed to dissect the key academia-industry/public sector-private sector interactions that made the development of this drug a success despite many barriers. A model to explain how and why bortezomib was approved in record time is presented, and areas for public-policy initiatives to improve translational research in general are highlighted.
- Subjects
DRUG development; ANTINEOPLASTIC agents; DRUG approval; PROTEASE inhibitors; ENZYME inhibitors; ANTIGENS
- Publication
Nature Reviews Drug Discovery, 2006, Vol 5, Issue 2, p107
- ISSN
1474-1776
- Publication type
research
- DOI
10.1038/nrd1959